Innovator & Entrepreneur in Biotechnology
Seattle, WA
Joined April 2009
- Tweets1.1K
- Following158
- Followers200
- Likes760
Can we please all agree to stop saying "The chatGPT moment for [insert tech/industry]..." as if it's just something that happens spontaneously because AI and [] both exist.
Christopher Pirie retweeted
(NEW EPISODE) He Raised $100 Million For A Company And Merged With Inscripta, And Is Now Converting Waste Into Valuable Products To Decarbonize The Chemicals Industry @CMPirie alejandrocremades.com/he-rai… #entrepreneur #business #success
Excited to be attending the #BBGGreenFestival hosted by @BloombergLive during #PNWCW2024 and participating in the Climate Tech Challenge from @LeanerStartups and a variety of other affiliated networking events.
Should be a busy and fun week.
Christopher Pirie retweeted
Awesome collaboration with the @McGuire_Lab now published! Use of @hdtbio’s LION/repRNA platform to prevent #EBV infection of humanized mice. nature.com/articles/s41541-0…
For everyone screaming that pharma is taking advantage of patients (fwiw it's generally the system not the companies), please take a look at this table at start focusing on how the banks and oil companies are taking advantage of main street.
pages.stern.nyu.edu/~adamoda…
Listening to @HeatherHartnett talk about founding team composition with aligned values and skill cross-section is really resonating. Clarity of purpose/accountability from the start is super important.
Christopher Pirie retweeted
HDT Bio recently spoke to Moira Gunn of @biotechnation to discuss the company’s progress in #RNAvaccine development and walk her through how our revolutionary repRNA/ LION™ platform works.
Listen here: bit.ly/44k4g3h
Christopher Pirie retweeted
This week on #BioTechNation, Dr. Chris Pirie, Co-Founder & COO of HDT Bio joins us to talk about their groundbreaking approaches to cancer prevention through vaccines. Listen Now: ow.ly/wTga50R6Ve2 #CancerPrevention #Vaccines
When starting a company myself or advising venture teams, I'm often faced with the question "How much should we raise?" While the answer is usually some variation of "It depends", I find that too often we don't consider the cultural and behavioral consequences of the choice.
Christopher Pirie retweeted
VC Fund size to DPI plot - 168 funds covered & Vintage year 2014-2016
1. Only ~20% are in the carry
2. >$2B barely returned deployed capital back to LPs (not including fees/hurdle)
3. Median fund size of $200M returned >1.5x DPI
Will post other thematic observations later
Christopher Pirie retweeted
Today, we announced the receipt of a $749,000 EZBAA contract through a partnership with @BARDA under #ProjectNextGen’s Enabler’s program. The contract will support studies providing proof-of-concept data for our #RNA #vaccine LION™ platform and more.
prnewswire.com/news-releases…
Biology is complex. But every day we get a little bit closer to understanding the nature of all its glory. @AngCuiPhD and her colleagues have brought us closer. If you're developing vaccines and haven't read this paper, you're doing yourself a disservice. @hdtbio
✨#ImmuneDictionary✨is out today in @Nature!
Paper nature.com/articles/s41586-0…
Software immune-dictionary.org
We created scRNA-seq dictionary of 17+ immune cell types responding to 86 cytokines in vivo, discovered the immune system is far more complex than previously known 1/
ALT The Immune Dictionary is a large-scale compendium of single-cell transcriptomic profiles of more than 17 immune cell types in response to each of 86 cytokines in vivo, a reference for understanding the complex immune system. The image lists the 86 cytokines, representing almost all major cytokines in the immune system, studied in the dictionary. For more information, see our Nature (2023) publication "Dictionary of immune responses to cytokines at single-cell resolution": https://www.nature.com/articles/s41586-023-06816-9
Christopher Pirie retweeted
Our Co-founder and COO Chris Pirie, Ph.D., (@CMPirie) and five other biopharma executives spoke with @BioWorld about financial struggles the biopharma space faced this past year, and why we’re optimistic for a better 2024.
bioworld.com/media/podcasts/…
Christopher Pirie retweeted
Enabling self-amplifying RNA vaccines with @hdtbio ‘s LION formulation. More on this in my interview with @VaccineInsights insights.bio/vaccine-insight…
Christopher Pirie retweeted
BARDA is partnering w/ @hdtbio under #ProjectNextGen’s Enablers program to support proof-of-concept studies for on-demand manufacturing & release processes that use HDT Bio’s LION formulation for mRNA vaccine production. Learn more about Project NextGen: ow.ly/FvSh50Q4QM1
Christopher Pirie retweeted
The results of a recent study published in @MolTherapy suggest that in vivo administration of repRNA by LION™, HDT Bio’s technology for delivering #RNA #vaccines, is safer than other formulation technologies.
Learn more: prnewswire.com/news-releases…
